Dr. Ali Keshavarzian, MD
Claim this profileRush University Medical Center
Studies Crohn's Disease
Studies Inflammatory Bowel Disease
4 reported clinical trials
5 drugs studied
Affiliated Hospitals
Clinical Trials Ali Keshavarzian, MD is currently running
Bright Light Therapy
for Crohn's Disease
Crohn's Disease (CD) and Ulcerative Colitis (UC), collectively known as inflammatory bowel disease (IBD), are two of the most significant chronic conditions of the gastrointestinal tract (GIT) and affects over 1.5 million individuals in the U.S. Recently, there has been an increased understanding of the importance of sleep and sleep disruption in IBD as a potentially modifiable risk factor. We, therefore, hypothesize that intervening with morning bright light therapy (BLT) in IBD patients with CM will decrease intestinal permeability and pro-inflammatory cytokines, positively impact intestinal microbiota, and improve quality of life (QoL).
Recruiting0 awards N/A
Prebiotics
for AUD and HIV/AIDS
Alcohol use disorder (AUD) has been associated with high prevalence of inflammation-associated co-morbidities in people living with HIV even those receiving effective antiretroviral therapy (ART). Our preliminary data support a model in which the combined insult of AUD and HIV on the gut, specifically on the microbiota and intestinal barrier integrity, exacerbates inflammation. Our preliminary data using intestinal organoids also suggest a potential mechanism for AUD-mediated changes in the gut barrier function during HIV; the intestines of HIV+ individuals have low resilience to alcohol induced intestinal barrier disruption caused by high levels of oxidative stress. Finally, our preliminary data also suggest a potential approach to enhance the integrity of the intestinal barrier and reduce gut derived inflammation in people living with HIV with/without AUD- short chain fatty acid prebiotics. These prebiotics prevent alcohol mediated adverse effects on the intestinal barrier and inflammation by preventing oxidative stress. These prebiotics are safe and decrease gut inflammation in humans. 20 HIV+ ART+ (10 AUD- and 10 AUD +), will be recruited for a prebiotic intervention. This is a proof-of-concept observational study to establish a causal link between microbiota-gut and HIV pathology during ART by asking whether modifying microbiota and gut milieu impacts intestinal barrier function, systemic inflammation, and brain pathology in HIV+ people. Participants will have two study visits, where stool collection and blood draw will be collected, as well as questionnaires. These participants are part of the larger observation study (n=160), which will test the hypothesis that intestines from HIV+ individuals have lower resilience to alcohol mediated gut barrier disruption than intestines from HIV-negative controls. We will recruit the following groups of participants: HIV+ ART+ AUD-; HIV+ ART+ AUD+; HIV- AUD- ; HIV- AUD+. Blood, urine, stool, and intestinal biopsies will be collected from participants to compare intestinal barrier integrity, system and gut inflammation, immune activation, oxidative stress, microbiome/metabolome. and HIV reservois. Second, lleal/colonic organoids from HIV- and HIV ART+ individuals will be generated to examine their resilience to alcohol-induced intestinal barrier disruption.
Recruiting1 award N/A10 criteria
More about Ali Keshavarzian, MD
Clinical Trial Related2 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Ali Keshavarzian, MD has experience with
- Bright Light Therapy
- Placebo Retimer Device
- Prebiotic
- Dietary Intervention
- 7-day Sleep Lab
Breakdown of trials Ali Keshavarzian, MD has run
Crohn's Disease
Inflammatory Bowel Disease
Alcoholism
Antiretroviral Therapy
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ali Keshavarzian, MD specialize in?
Ali Keshavarzian, MD focuses on Crohn's Disease and Inflammatory Bowel Disease. In particular, much of their work with Crohn's Disease has involved treating patients, or patients who are undergoing treatment.
Is Ali Keshavarzian, MD currently recruiting for clinical trials?
Yes, Ali Keshavarzian, MD is currently recruiting for 2 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that Ali Keshavarzian, MD has studied deeply?
Yes, Ali Keshavarzian, MD has studied treatments such as Bright Light Therapy, Placebo Retimer Device, Prebiotic.
What is the best way to schedule an appointment with Ali Keshavarzian, MD?
Apply for one of the trials that Ali Keshavarzian, MD is conducting.
What is the office address of Ali Keshavarzian, MD?
The office of Ali Keshavarzian, MD is located at: Rush University Medical Center, Chicago, Illinois 60612 United States. This is the address for their practice at the Rush University Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.